Anzeige
Mehr »
Login
Dienstag, 03.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Eilmeldung: Goldshores aggressiver Winter-Explorationsplan nimmt Gestalt an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AC9U | ISIN: US45781M1018 | Ticker-Symbol: HVE
Tradegate
03.12.24
10:35 Uhr
18,200 Euro
0,000
0,00 %
1-Jahres-Chart
INNOVIVA INC Chart 1 Jahr
5-Tage-Chart
INNOVIVA INC 5-Tage-Chart
RealtimeGeldBriefZeit
17,90018,20019:39
17,90018,20019:39

Aktuelle News zur INNOVIVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.11.Innoviva GAAP EPS of $0.02, revenue of $89.51M beats by $12.59M1
07.11.Innoviva Inc reports results for the quarter ended in September 30 - Earnings Summary2
06.11.Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress31BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious...
► Artikel lesen
06.11.Innoviva, Inc. - 10-Q, Quarterly Report-
06.11.Innoviva, Inc. - 8-K, Current Report-
31.07.Innoviva GAAP EPS of -$0.55, revenue of $99.9M1
31.07.Innoviva, Inc. - 10-Q, Quarterly Report1
31.07.Innoviva, Inc. - 8-K, Current Report1
INNOVIVA Aktie jetzt für 0€ handeln
31.07.Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress69BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious...
► Artikel lesen
20.06.Innoviva, Inc. - 8-K, Current Report1
18.06.Cantor starts Innoviva at overweight, cites diversified business model2
18.06.Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs11
08.05.Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress117BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious...
► Artikel lesen
24.04.Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024316Single-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be...
► Artikel lesen
29.02.Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress216BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1